ANTICOAGULATION DURING CONTINUOUS RENAL REPLACEMENT THERAPY: AN UPDATE.

Theodoros Aslanidis, Paschalia Karakosta, Athena Myrou

1 Anesthesiology-Intensive Care / Pre-hospital Emergency Medicine, Intensive Care Unit, St. Paul General Hospital, Thessaloniki, Greece
2 Nephrology, Intensive Care Unit, St. Paul General Hospital, Thessaloniki, Greece
3 Internal Medicine-Intensive Care, Private Sector, Thessaloniki, Greece

Received May 20, 2019, Revised June 6, 2019, Accepted June 11, 2019

Abstract

Renal replacement therapy in Intensive Care Units is a daily practice worldwide. Ensuring blood flow continuum within extracorporeal circuit is one of the basic tasks during therapy. Unfractionated heparin remains the most popular anticoagulant used. Alternatives, such as low molecular weight heparins, prostacyclin, fondaparinux, or regional use of citrate or nafomostate mesilate are also gaining ground, mainly due to their safety profile. Still, there is no worldwide consensus about their use. Systemic, regional, combined or no coagulation at all; the final choice depends on the patients’ characteristics and co-morbidities, as well as institutional and organizational protocols, equipment availability and staff education. This article presents a review of the current modalities for anticoagulation during continuous renal replacement therapy.

Keywords: anticoagulation; continuous renal replacement therapy

Introduction

Acute renal dysfunction is substantially contributing to morbidity and mortality among critically ill patients. In the intensive care unit (ICU) renal replacement therapy (RRT) has proven its role in the management of patients with – acute and chronic - renal failure; although reports about long-term outcome of these patients are controversial.

RRTs include intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapies (CRRTs), and hybrid therapies such as prolonged intermittent renal replacement therapies (PIRRTs), which provide prolonged but still intermittent dialysis. Narrower terms used to describe PIRRT include sustained low-efficiency (daily) dialysis (SLEDD), sustained low-efficiency (daily) diafiltration (SLEDD-f), extended daily dialysis (EDD), slow continuous dialysis (SCD), go slow dialysis, and accelerated venovenous hemofiltration (AVVH).

In general, RRT therapy is chosen based upon the patients’ characteristics and institutional availability. In the dynamic ICU environment, CRRTs are the most popular type of RRT, as it is related to fewer episodes of hemodynamic instability and better control of fluid balance.

One of the most essential issues during CRRT is ensuring continuous extracorporeal blood flow without clotting, both within the circuit (especially in central venous catheter for RRT) and the artificial filter. However, anticoagulation strategy during CRRT needs special attention and balancing between the life of the artificial extracorporeal circuit and the danger for patient bleeding.

The current article provides a review of the literature about the methods of anticoagulation during CRRT.

Unfractionated Heparin

Unfractionated heparin (UFH) is a heterogeneous mixture of glycosaminoglycans with molecular weight 5000–30000 Daltons kiloDaltons. It acts by forming a complex with antithrombin III (ATIII), catalyzing the inhibition of several activated (a) blood coagulation factors: thrombin (factor IIa),...
Christmas factor (FIXa), Stuart factor (FXa), plasma thromboplastin antecedent (factor XIa) and Hageman factor (FXIIa). UFH is metabolized by the liver and metabolites are excreted by the kidneys. Heparin is heterogeneous in regard not only to its molecular weight but also to its anticoagulant effects and its pharmacokinetics. Its half life is dose-dependent ranging from 30 to 180 minutes. However, it is considered as the classic choice for anticoagulation during CRRT, mainly because of its low cost, high availability and ease of administration.

Dosing of UFH during CRRT is usually based on measured activated partial thromboplastin time (APTT) or activated clotting time (ACT). The target treatment for APPT ratio is between 1.2–1.5 and 120–180 sec for ACT.

In practice, development of local (bedside) protocols should be used. Each protocol includes every aspect of UFH anticoagulation during CRRT and incorporates possible local characteristics (institutional, organizational). Key points in every protocol: 1) the need or not for priming the circuit before initiation of therapy, 2) starting dose, 3) monitoring parameters, measuring interval and target, 4) modification of dose, 5) other (e.g. handling complications and emergencies). A parallel quality assurance strategy (staff education, assessment meetings, etc.) should also be in place. In general, a filter life of 20–24 h is common when a UFH anticoagulation protocol is „working”.

A simple example of such protocol is displayed table 1.

Despite its popularity, UFH should be administered with caution during CRRT. First of all, because the basic assay for monitoring UFH therapy (APPT) is just a surrogate marker for estimation of heparin concentration, which is susceptible to several cofounding factors. In other conditions, like deep venous thrombosis, weight-based nomograms have been suggested in order to overcome difficulties delivering UFH. Yet, in CRRT several authors claim that Anti-Factor Xa (anti-FXa) levels may provide better and more reliable monitoring; however, even these levels show considerable inter-laboratory variation, and there are insufficient clinical studies proving improved clinical efficacy.

The above creates additional problems in a seemingly simple problem: UFH reversal. Protamine dosing is generally 1–1.5 mg per 100 UI of Heparin, yet time elapsed from heparin administration modifies the regimen to 0.5–0.75 mg / 100 units UFH if 30–120 min has passed, or 0.2–0.375 mg/100 UI UFH, if time elapsed is > 2 h. APPT should be monitored 5–15 min after dose and then every 2–8 h. Some authors suggest an alternative to sole UFH protocol, with Heparin administration (at 1000 UI/h) prefilter and protamine administration (at 10 mg/h or 1:100 ratio) postfilter into venous chamber or directly into the return limb of the access catheter (via a suitable Y piece, but not a three-way tap). In any case, attention is needed because protamine can trigger serious adverse effects, such as anaphylactoid reactions, hypotension and catastrophic pulmonary vasoconstriction.

Along with that, UFH use is not without complications. Bleeding, defined as a decrease in hemoglobin ≥ 1.5 gr/dl, below the level at initiation of CRRT often leads to transfusion of one or more units of red blood cells.

Table 1. An example of UFH CRRT protocol (authors’ protocol).

| APTT (seconds) | Bolus dose | Rate change |
|---------------|------------|-------------|
| <40           | 1000-2000 UI* | +200 UI/h (do not exceed 20UI/kg/h) |
| 40.1–45       | Nothing    | +100UI/h (do not exceed 20UI/kg/h) |
| 45.1–55       | Nothing    | No change   |
| 55.1–65       | Nothing    | Stop 30 min and -100 UI/h |
| >65           | Nothing    | Stop 1h and -200UI/h |

*UI: International Units
Heparin solution: 1ml of 10000 U/ml of UFH in 19 ml of NaCl 0.9% (500U/ml)
Initial bolus 20 UI/kg, followed by infusion of 5 UI/kg/h
Monitoring APTT/ 4h
blood cells. In case of increased (bleeding) risk, higher circuit blood flow is recommended.

Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. HIT Type I caused direct effect of heparin on platelets and HIT II is caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. In patients in CRRT, HIT II is usually observed. Clinically, thrombocytopenia with both arterial and venous thrombosis is the main feature of HIT II. Additionally, recent reports suggest that CRRT per se may also be a thrombocytopenia-related factor. Regardless of the latter, HIT probability should be calculated in all patients before CRRT, either via 4Ts Score or by newer HIT Expert Probability (HEP) score. While the 4Ts score system calculates the risk for HIT after considering selected parameters (Table 2), the HEP score uses more variables such as skin necrosis, acute skin reaction and the presence of bleeding.

In general, patients with a baseline APPT > 55 sec, platelet count < 40000/mm³, allergy in heparin, prior history of heparin induced thrombocytopenia or high 4Ts or HEP score, incident of intracranial or gastrointestinal hemorrhage within the previous three months, active bleeding or significant trauma within 3 days and evidence of irreversible coagulopathy because of liver failure should not receive heparin during CRRT.

Other side effects of UFH are hypertriglyceridemia (releases and depletes endothelium-bound lipoprotein lipase), osteoporosis and hypocalcemia. Furthermore, it should be kept in mind that conditions, like sepsis or systemic inflammation, require special caution due to reduction of ATIII concentration as a result of its consumption or proteolytic degradation. In the latter, an ATIII supplementation protocol has been suggested. The supplementation protocol aims to achieve a plasma ATIII level greater than 110 to 120%. Each time that ATIII activity drops below 70% (measurement before CRRT), 50 UI/kg ATIII is administered intravenously. The fixed daily 50 UI/kg dose regimen of ATIII supplementation is chosen because of the 1.7% per UI/kg AT response and a mean half-life of 18.9 hours are expected in these patients, as reported.

**Low Molecular Weight Heparins**

During the last decades, low molecular weight heparin (LMWHs) are replacing UFH as anticoagulants in CRRT. This increasing tendency, despite

### Table 2. HIT score

Applying the scoring system to suspected patients produces a totalled score between 0 and 8. Scores of 0 to 3, 4 to 5, and 6 to 8 are respectively classified as low, moderate, and high probability for HIT.

| Points                     | Thrombocytopenia | Timing of PLT fall | Thrombosis or other sequelae | Other causes of thrombocytopenia |
|----------------------------|------------------|--------------------|-----------------------------|---------------------------------|
|                            | 2                | 3                  | 0                           |                                 |
| >50% fall or PLT nadir     | 30-50% fall or PLT nadir | <30% fall or PLT nadir | None                        |
| >20 x 10⁹ L⁻¹             | 10-19 x 10⁹ L⁻¹ | 10 x 10⁹ L⁻¹       |                             |
| Clear onset between days 5 and 10 or platelet fall ≤ 1 day (prior heparin exposure within 30 days) | Consistent with days 5–10 fall, but not clear (e.g. missing platelet counts) or onset after day 10 or fall ≤ 1 day (prior heparin exposure 30–100 days ago) | Platelet count fall < 4 days without recent heparin exposure |
| New thrombosis (confirmed) or skin necrosis at heparin injection sites or acute systemic reaction after intravenous heparin bolus | Progressive or recurrent thrombosis or non-necrotizing (erythematous) skin lesions or suspected thrombosis (not proven) |                             |
| None apparent              | Possible         | Definite           |                             |
the higher cost, could be attributed to the clinical benefits of LMWHs over UFH (Table 3).

| Characteristic               | UFH       | LMWHs    |
|------------------------------|-----------|----------|
| Availability for antithrombin reaction | 30%       | >85%     |
| AntiXa/AntiIIa ratio         | 1:1       | >2-9.7:1 |
| Molecular weight-(MW) (kDa)  | 15 (4-30) | 4.5 (2-10) |
| Half-time (T₁/₂)              | Short (~1h, dose-dependent) | Longer, more predictable |
| Bioavailability              | Low       | Higher than UFH |
| Dosage regiment              | Frequent  | Less frequent |
| Clearance                    | Hepatic   | Renal    |
| Bleeding tendency            | High      | Lower than UFH |
| Thrombocytopenia             | High      | Lower than UFH |
| Osteoporosis propensity      | High      | Lower than UFH |
| Therapeutic response         | Variable  | Predictable |
| Reversal                     | Fully with protamine | Partially with protamine |
| Laboratory monitoring        | Essential | See text for monitoring* |

Table 3. Comparative statements between UFH and LMWHs⁹,¹⁰,³⁰,³¹.

LMWHs are produced by depolymerization of the long oligosaccharide chains of UFH into smaller chains. The different depolymerization methods (chemical or enzymatic β-elimination, oxidative cleavage or nitrous depolymerization) result in LMWHs with distinct characteristics (Table 4).

Tests for monitoring LMWHs include anti-factor Xa (anti-FXa), activated partial thromboplastin time (APTT) and thrombin generation. Since they have predominantly anti-FXa activity, it is appropriate to monitor their levels by an anti-FXa chromogenic assay (detection limit of 0.01 UI/ml). Therapeutic levels are defined as 0.5–1 UI/ml and levels below 0.5 UI/ml are considered insufficient, while above 1 UI/ml are considered excessive anticoagulation.⁹⁴¹. Thrombin generation with tissue factor-rich activator is an alternative promising method for monitoring LMWHs⁴².

Heparin complications (Bleeding, HIT) can also be triggered by LMWHs, although less often and in milder forms.¹⁰. In case of hemorrhage due to overdose, protamine is not as efficient as in UFH overdose and fresh frozen plasma (FFP) or recombined activated factor VII (rFVIIa) may be needed⁴³.

Their longer half-time, low affinity to endothelial cells, plasma proteins, macrophages and absence of clearance by the different modes of RRT, allow for a single bolus dose at start of therapy, in case of intermittent hemodialysis or PIRRT.⁸ For CRRT, the most adopted strategy is either an initial bolus followed by a continuous infusion or intermittent boluses every 6 hours.⁴⁶ An alternative regimen is to omit the loading dose and simply start with a continuous intravenous infusion (civ) (Table 5).

**Dermatan sulfate**

Dermatan sulfate is a natural heparinoid that also has been used for CRRT anticoagulation. It acts by selectively inhibiting thrombin and does not inhibit factor Xa and does not interfere with platelets. Dosing include a bolus loading of 150 mg followed by an infusion of 12–13 mg/h.⁵². Measuring APPT is suggested as monitoring method.
Danaparoid is a low molecular weight (5 kDa) heparinoid glycosaminoglycuronan antithrombotic agent that contains a mixture of heparan sulfate (84%), dermatan sulfate (12%) and chondroitin sulfate (4%). It acts mainly via ATIII and on factor IIa (Anti-Xa / Anti-IIa activity ratio > 20:1). In CRRT, it has been used in patients with high risk of HIT in the following dosing regiments: 1) 750UI loading bolus followed by 50-150UI/h civ or 2) 3500 UI bolus followed by 100 U/h civ, aiming at anti-Xa levels of 0.5–0.7 U/ml.

Fondaparinux

Fondaparinux is the only synthetic pentasaccharide factor Xa inhibitor (Table 5) that has been used in CRRT.

Yet, data are limited to case reports or case series. In such a case (patient with HIT type II), dosing regimen of 2.5 mg instilled directly into the dialysis circuit was chosen; while in case of RRT (Intermittent Hemodialysis), fondaparinux 0.05 mg/kg actual body weight was administered on days of dialysis. Dosing was increased to a maximum dose of 0.08 mg/kg actual body weight based on anti-factor Xa levels. Still, the optimal fondaparinux dosage remains unknown. Thus, peak

---

**Danaparoid**

**Fondaparinux**

---

Table 4. Comparative table of LMWHs.

| Brand Name | MW (kDa) | T1/2 (h) | Bioavailability (%) | AntiXa/AntiIa ratio | AntiXa activity (UI/mg) |
|------------|----------|----------|---------------------|---------------------|------------------------|
| Nadroparin | 4.3      | 3.7      | 89                  | 3.5                 | 100                    |
| Enoxaparin | 4.5      | 4.5      | 90-92               | 3.8                 | 100                    |
| Dalteparin | 6        | 3-5      | 87                  | 2.7                 | 156                    |
| Bemiparin  | 3.6      | 5.1      | 96                  | 8.1                 | 110                    |
| Certoparin | 5.4      | 6        | >90                 | 2.4                 |                        |
| Parnaparin | 5        | 4        | ~100                | 2.3                 |                        |
| Reviparin  | 4.4      | 3        | 95                  | 4.2                 | 124                    |
| Tinzaparin | 6.5      | 3.4      | 87                  | 2.8                 | 100                    |
| Ardeparin  | 5.5-6.5  | 3.3      | 92                  | 1.7-2.4             |                        |

Table 5. Examples of LMWHs used for CRRT.

| LMWH used | Initial bolus | Maintenance dose | Anti FXa –level activity (UI/ml) | Monitoring interval |
|-----------|---------------|------------------|----------------------------------|---------------------|
| Enoxaparin [44] | 0.15 mg/kg | 0.05 mg/kg/h | 0.25-0.3 | 6h |
| Enoxaparin [45] | 0.5-0.7 mg/kg/12h | 0.5-1 | 12h |
| Enoxaparin [46] | 1.5mg/kg per 24h | 0.07-1.26 | 6h |
| Enoxaparin [47] | 0.5 mg/kg | 1mg/kg/day | 0.29 | |
| Tinzaparin [48] | 400-800 UI/h | * | * |
| Nadroparin [49] | 0.6 ml | 0.3 ml/4h | * | * |
| Dalteparin [50] | 600 UI/h | 0.3-08 | * |
| Dalteparin [51] | 2000 UI | 320 UI/h | 0.5-1 | * |

*not available*
anti-factor Xa concentrations may be essential for guiding therapy.\textsuperscript{59}

**Hirudin, Lepirudin and Bivalirudin**

Hirudin and its analogs, lepirudin (recombinant hirudin) and bivalirudin, act independently of PF4 and cofactors; thus has been used as an alternative in patients with HIT\textsuperscript{60–66}. For CRRT, lepirudin is administered either as a continuous infusion (0.005–0.01 mg/kg/h) or delivered in bolus doses (0.2 mg/kg); while bivalirudin is administered pre-filter in 0.009–0.023 mg/kg/h (1–2.5mg/h)\textsuperscript{62–66}. Although, APPT can be used as monitoring tool (aiming at 1.5–2.5 times baseline), there is no linear correlation with anticoagulation activity. Instead specialized tests such as ecarin clotting time (ECT) or hirudin ELISA have been suggested. Target for ECT during CRRT is 80–100 sec\textsuperscript{64}. In case of bleeding, no antidote exists and rFVIIa or FFP may be needed. Yet, in general, results from its use in CRRT are comparable with UFH protocols\textsuperscript{67–69}.

**Argatroban**

Argatroban is a monovalent direct thrombin inhibitor (DTI) with hepatic metabolism and a short half time (35 min). Although it does not require a dosage adjustment in patients with renal dysfunction or in patients undergoing RRT, up to 22% of the drug is renally excreted; thus, caution is needed\textsuperscript{70}. Half time may increase to 2.7 in cardiac surgical critical ill patients with HIT\textsuperscript{71}. Monitoring is usually achieved via APTT or activated clotting time (ACT) measurements; although recent studies suggest thrombin time (TT) and rotational thromboelastometry (ROTEM) as better alternatives\textsuperscript{72}. Data about dosing vary: 1) initiation at 0.2 μg/kg/min at up to 3.1 μg/kg/ min in accordance to APTT\textsuperscript{73} 2) start at 0.5 μg/kg/ minute, and adjustment in 0.1–0.25 μg/kg/minute increments\textsuperscript{71} or 3) a loading dose of 100 μg/kg followed by a maintenance infusion rate (μg/kg/ min), which can be calculated from the scores as follows: for Acute Physiology and Chronic Health Evaluation (APACHE)-II: 2.15–0.06 x APACHE II; for Simplified Acute Physiology Score (SAPS) II: 2.06–0.03 x SAPS II; and for indocyanine green plasma disappearance rate (ICG-PDR): -0.35 + 0.08 x ICG-PDR\textsuperscript{74}.

**Oral Direct thrombin inhibitors, Direct factor X inhibitors and Warfarin**

This group includes the oral DTI dabigatran and the factor X inhibitors apixaban, rivaroxaban and edoxaban. Given the need for oral access without the current ability to assess adequate absorption and level of anticoagulation with these drugs, this is likely to limit their use in CRRT\textsuperscript{75}. Although vitamin K antagonist warfarin has been studied in intermittent hemodialysis, there are no data for use in CRRT\textsuperscript{76–78}.

**Tirofiban**

Tirofiban, an antiplatelet agent, is the only glycoprotein IIB/IIA inhibitor (the group includes also abciximab and eptifibatide) used in RRT. Tirofiban in dose regimen 0.2 μg/kg/min bolus over 30 min followed by 0.05 μg/kg/min civ. has been used in conjunction with UFH (APTT target 2–3 times normal range) in patients with cardiogenic shock and acute kidney injury requiring CRRT\textsuperscript{77}.
In polimixina-B hemoperfusion a loading dose of 250 μg/kg has also demonstrated good results.

**Prostacyclin**

Prostacyclin (PGI$_2$) and other prostanoids have been used alone or in combination with UFH and LMWHs in CRRT. Whereas their vasodilatating effect lasts for 2 minutes, their antiplatelet effect continues for over 2 hours. Dosing in CRRT is 4–10 ng/kg/min iv. Limiting hypotension is achieved either by titrating to 0.5 ng/kg/min at the initiation of therapy or by restricting infusion at extracorporeal circuit only. Other side effects include minimal increase in intracranial pressure (especially in hepatic failure), nausea, vomiting, chest pain, anxiety, bradycardia, tachycardia, dyspnea, abdominal pain and ventilation perfusion mismatch (clinically significant in those with reflex hypoxic pulmonary vasoconstriction). ROTEM can be used in monitoring of anticoagulant effect. Apart from hypotension and difficulty of monitoring, PGI$_2$ cost is another drawback for its wider application.

**Nafomostate mesilate**

Nafomostate mesilate (NM) is a synthetic proteinase inhibitor with short half life (5–8 min). It acts on plasmin, trypsin, kalikrein, thrombin, factor Xa and XIIa and tissue factor-factor VIIa complex. It has no antidote and serious side effects include agranulocytosis, hyperkalemia and anaphylactoid reactions. Yet, the use of NM as an anticoagulant during CRRT is associated with decreased incidence of bleeding complications compared with the use of UFH. Data about its use in CRRT comes mainly from Japan, where it is the most frequent CRRT anticoagulant. Filter is primed with 500 solution of NaCl 0.9% with 20 mg NM and then a maintenance infusion of 10–30 mg/h is administered. Monitoring is performed via APTT or ACT.

**Citrate anticoagulation**

Citrate is a small (191 Da) negative charged molecule that acts by forming citrate-calcium (ionized-iCa) complexes, thus depleting an essential co-factor of the coagulation process. Citrate-iCa molecules are freely filtered and lost in effluent. The rest is metabolized in liver. Each molecule complex releases 3 molecules carbonate and 5 molecules calcium to circulation. The above create several difficulties during CRRT. For achieving anticoagulant effect citrate infusion is adjusted to blood flow in targeting a concentration of 3–6 mmol/l or aiming at a postfilter concentration of iCa of less than 0.35 mmol/l or postfilter ACT 200–250 sec. Since calcium is removed from the circulation, calcium infusion is added in order to maintain normal concentration range. Monitoring about metabolic derangements (hyponatremia, hypercalcemia, hypocalcemia, metabolic acidosis or alkalosis) and appropriate adjustments in citrate and calcium infusions are also essential during RRT. For example, accumulation of citrate due to decreased metabolism can be detected accurately by the symptoms of metabolic acidosis, increasing anion gap, ionized hypocalcemia, and most specifically by an increased total/iCa concentration (a ratio > 2.1 has 89% sensitivity and 100% specificity in predicting citrate concentrations). In recent years, regional citrate anticoagulation (RCA) in CRRT has become increasingly attractive due to its beneficial low bleeding risk problem. Bai’s meta-analysis study demonstrated that regional citrate anticoagulation for CRRT could prolong the filter lifespan and decrease the bleeding risk, compared with heparin anticoagulation. And the KDIGO guideline for AKI recommended RCA rather than heparin in patients who do not have contraindications for citrate. Even in liver failure (LF) patients considering the accumulation of citrate, a recent systematic review and meta-analysis pooled ten observational studies and demonstrated that the RCA might be safe and effective for LF patients underwent CRRT.

No anticoagulation, managing contributing factors and other alternatives

No matter how important anticoagulation strategy is, filter life and efficiency is depending on other numerous factors. A recent meta-analysis favors higher blood flow rates and continuous veno-venous hemodiafiltration (CVVHDF) over continuous veno-venous hemofiltration (CVVH). CRRT has also been performed without anticoagulation with 100–150 ml NaCl 0.9% circuit flush.
/ hour. Along with that, technology membranes’ progresses over the last years are moving towards limiting anticoagulation needs. Future research might enable use of other intravenous anticoagulant or antiplatelet agents during CRRT (e.g. the adenosine diphosphate receptor inhibitor cangrelor, the tromboxane receptor antagonist terutroban, the phosphodiesterase inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole).

**Conclusion**

There are several choices for anticoagulation during CRRT. Yet, the decision to use one over another is a complex task. On one hand, the patient’s condition, comorbidities and special characteristics; on the other hand, organizational/ institutional factors, staffing and level of education/experience, type/modes of RRT used, availability of agents chosen and application of a quality assurance program are determinants of the decision about both the anticoagulant and the protocol to be followed.

**Author Disclosures:**

Authors Aslanidis Th, Karakosta P, and Myrou A, have no conflicts of interest or financial ties to disclose.

**References:**

1. The RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients N Engl J Med. 2009; 361:1627–1638.

2. Rachoijn JS, Weisberg LS. Renal Replacement in the ICU. Crit Care Med. 2019.

3. De Corte W, Dhondt A, Vanholder R, et al. Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study. Crit Care. 2016; 20(1):256.

4. Edrees F, Li T, Vijayan A. Prolonged Intermittent Renal Replacement Therapy. Adv Chronic Kidney Dis. 2016; 23(3):195–202.

5. Kielstein JT, Golper T. Prolonged Intermittent Renal Replacement Therapy. Adv Chronic Kidney Dis. 2016; 23(3):195–202.

6. Kielstein JT, Golper T. Prolonged Intermittent Renal Replacement Therapy. *In* Berns J, Palevsky P (Eds). Update. 2018.

7. Heung M, Yessavan L. Renal Replacement Therapy in Acute Kidney Injury: Controversies and Consensus. Crit. Care Clin. 2017; 33(2):365–378.

8. Bagshaw, SM, Berthiaume, LR, Delaney, A, Bellomo, R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008; 36:610–617.

9. Brandenburger T, Dimski T, Slowinski T, Kindgen Miles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31(3):387–401.

10. Weitz JI, Harenberg J. New development in anticoagulants: past, present, future. Thromb Haemost. 2017; 117(7):1283–1288.

11. AHFS Drug Information 2018. McEvoy GK, ed. Heparin Sodium. Bethesda, MD: American Society of Health-System Pharmacists; 2018.

12. Hirsh J, Warkeinten TE, Shaughnessy SG, Anand SS, Halperin JI, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(1 suppl):645–94S.

13. Karakala N, Tolmani A. We use heparin as the anticoagulant for CRRT. Semin Dial. 2016; 29(4):272–4.

14. Kielstein NT, Golper T. Prolonged Intermittent Renal Replacement Therapy: Issues and Recommendations. Semin Dial. 2016; 29(4):272–4.

15. Marlar RA, Clement B, Gausman J. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Anticoagulation: A review of the pharmacology, dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2):83–97.

16. Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2):83–97.

17. Dhakal P, Rayamaghi S, Verma V, Gundabolu K, Bhatt VR. Reversal of anticoagulation and management of bleeding in patients. Clin Appl Thromb Hemost. 2017; 23(5):810–3.

18. Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. 2017 Apr; 43(3):253–260.

19. Arachchilage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin? Thromb Res. 2017; 157:157–161. Doi: 10.1016/j.thromres.2017.07.006.

20. Dhakal P, Rayamaghi S, Verma V, Gundabolu K, Bhatt VR. Reversal of anticoagulation and management of bleeding in patients. Clin Appl Thromb Hemost. 2017; 23(5):410–415.

21. Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. 2017 Apr; 43(3):253–260.

22. Heung M, Yessavan L. Renal Replacement Therapy and Anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31(3):387–401.

23. Brandenburger T, Dimski T, Slowinski T, Kindgen Miles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31(3):387–401.
24. Holmes CE, Huang JC, Cartelli C, Howard A, Rimmer J, Cushman M. The clinical diagnosis of heparin-induced thrombocytopenia in patients receiving continuous renal replacement therapy. J Thromb Thrombolysis. 2009; 27(4):406–12.

25. Pishko MA, Fardin S, Lefer SD, Paydary K, Vega R, Arepally MG, Crowther M, Rice L, Cines DB, Cuke A. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv. 2018; 2(22):3155–3162.

26. Kutsogiannis DJ, Gibney RT, Strolley D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005; 67(6):2361–2367.

27. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast B, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006; 34(2):285–292.

28. du Cheyron D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P Antithrombin supnplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study. Crit Care. 2006; 10(2):R45.

29. Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, Keinecke HO, Heinrichs H, Thijis LG. Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med. 2000; 26:704–715.

30. Akhtar F, Wan X, Wu G, Kesse S, Wang S, He S. Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes. Molecules. 2018; 23(7):1757. Doi:10.3390/molecules23071757.

31. Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin Appl Thromb Hemost. 2017; 23(5):410–415.

32. Samama MM, Gerotzias GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000; 26 Suppl 1:31–38.

33. Jeske W, Wolf H, Ahsan A, Fareed J. Pharmacologic profile of certoparin. Expert Opin Investig Drugs. 1999; 8(3):315–27.

34. von Tempelhoff G, E Harenberg J, Niemann F, Hommel G, Kirkpatrick C, J, & Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. International Journal of Oncology. 2000; 16:815–824.

35. Camporese G, Bernardi E, Noventa F Update on the clinical use of the low-molecular-weight heparin, certoparin. Vasc Health Risk Manag. 2009; 5:819–31.

36. Frampton JE, Faulds D. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs. 1994; 47(4):652–676.

37. Al-Saran KA, Sabry A, Taha M, Ghafoor MA, Al Fawzan F. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. Saudi J Kidney Dis Transpl. 2010; 21(1):43–49.

38. Hoppensteadt D, Jeske W, Fareed J. Pharmacological profile of reviparin-sodium. Blood Coagul Fibrinolysis. 1993; 4 Suppl 1:S11–16.

39. Harenberg J, Haaf B, Dempflè CE, Stehle G, Heene DL. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant. 1995; 10(2):217–222.

40. Helviz Y, Dzigivker I, Raveh-Brawer D, Hersch M, Zevin S, Elhar Y. Anti-faror Xa activity of prophylactic enoxaparin regimens in critically ill patients. Isr Med Assoc J. 2016; 18(2):108–113.

41. Gosselin RC, Francart SJ, Hames EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated chromogenic Anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015; 49(7):777–783.

42. Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS One. 2015; 10(1).

43. Davenport A. Anticoagulation for acute dialysis. Springer Berlin Heidelberg; Management of acute kidney problems. 2010; 559–575.

44. Joannidis M, Kountchev J, Rauchenzauner M, Schusterschitz N, Ulmer H, Mayr A, Bellmann R. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med. 2007; 33(9):1571–1579.

45. Garcés EO, Victorino JA, Thomé FS, Röhsig LM, Dornelles E, Louzada M, Stift J, de Holanda F, Veronese FV. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Ren Fail. 2010 Jan; 32(3):320–7.

46. Tsang DJ, Tuckfield A, Macisaac CM. Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy. Crit Care Resusc. 2011; 13(1):24–7.

47. Reeves JH, Graan M. Randomised Controlled Trial Enoxaparin versus Heparin in Continuous Renal Replacement Therapy. Blood Purif. 2003; 21:199.

48. M. Voiculescu, G.Ismail, C.Ionescu, D. Micu, A. Szigeti. Anticoagulation Efficacy and Safety with a Low-Molecular-Weight Heparin – Tinzaparin in Continuous Renal Replacement Therapy. Blood Purif. 2002; 20:305–323.

49. D. Schepens, B. De Keulenaer ACZA Stuivenberg. Efficacy and Safety of Nadroparine as Anticoagulant Therapy in Continuous Venovenous Hemofiltration. Blood Purif. 2002; 20:305–323.

50. Ullas E, Karjalainen M, Vaara S, Reinikainen M. Anticoagulation for continuous renal replacement therapy in the intensive care unit: a comparison of dalteparin infusion with regional citrate anticoagulation. Duodecim. 2015; 131(11):1079–1084.

51. de Pont ACJM, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high volume continuous venovenous hemofiltration: a double-blind randomized cross-over study. Blood Purif. 1997; 15:132.
52. Vitale C, Verdechcia C, Bagnis C, Ganzaroli M, Gioccelli G, Marangella M. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy. J Nephrol. 2008; 21(2):205–212.

53. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparin (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost. 2001; 7(4):300–304.

54. de Pont AC, Hofstra JJ, Pik DR, Meijers JC, Schultz MJ. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Crit Care. 2007; 11(5):R102.

55. Harenberg J. Development of idraparinux and idrabioparinux for anticoagulant therapy. Thromb Haemost. 2009; 102:811–815.

56. Haase M, Bellomo R, Rocktaeschel J, Ziemen S, Kiesewetter H, Morgera S, Neumayer HH. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II. Nephrol Dial Transplant 2005; 20:444–446.

57. Kalicki RM, Aregger F, Lammle B, Frey FJ, Uehlinger DE. Use of the pentasaccharide fondaparinux as an anticoagulant during hemodialysis. Thromb Haemost. 2007; 98:1200–1207.

58. Cope J, Bushwitz J, An G, Antigua A, Patel A, Zumbig M. Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. Ann Pharmacother. 2015; 49(3):270–277.

59. Hoste EAJ, Dhondt A. Clinical review: Use of renal replacement therapies in special groups of ICU patients. Critical Care 2012; 16:201.

60. Potosch B, Madleener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77:920–925.

61. Fischer KG van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int 1999; 56(Suppl. 72):S46–S50.

62. Kern H, Ziemen S, Kox WJ: Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med 1999; 25:1311–1314.

63. Hein OV, von Heymann C, Lipps M, Ziemen S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001; 27:673–679.

64. Heim OV, von Heymann C, Diehl T, Ziemen S, Ronco C, Morgera S, Siebert G, Knox WJ, Neumayer HH, Spies C. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail 2004; 26:297–303.

65. Mueller SW, MacLaren R, Fish DN, Kiser TH. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother. 2009; 43(7):1360–5.

66. Gajra A, Vajpayee N, Smith A, Poiesz BJ, Narsipur S. Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy. J Am Hosp Med. 2007; 82(5):391–393.

67. Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy. 2010; 30(11):1117–26.

68. Abel EE, Kane-Gill SL, Seybert AL, Kellum JA. Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes, Am J Health Syst Pharm. 2012; 69(18):1559–1567.

69. Argatroban [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2016.

70. Keyl C, Zimmer E, Bek MJ, Wiessner M, Trenk D. Argatroban pharmacokinetics and pharmacodynamics of danaparoid in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. Thromb Haemost. 2016; 115(6):1081–9.

71. Beiderlinden M, Werner P, Bahlmann A, et al. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry — a prospectively controlled randomized double-blind clinical trial. BMC Anesthesiol. 2018; 18(1):18.

72. Jonathan H. Sin, Natasha D. Lopez. Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Hemofiltration. J Extra Corp Technol. 2017; 49(2):115–112.

73. Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009; 37(1):105–110.

74. Burcham PK, Rozycki AJ, Abel EE. Considerations for analgesedation and antithrombotic management during extracorporeal life support. Ann Transl Med. 2017; 5(4):69.

75. Poux JM, Dardim K, Nguyen QT, Arnaud G, Rouby MP, Manescu M. Thrice-weekly warfarin administration: results in 12 hemodialysis patients. Nephrol Ther. 2013; 9(6):426–432.

76. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007; 50(3):433–440.

77. Harel Z, Chertow GM, Shah PS, et al. Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Can J Cardiol. 2017; 33(6):737–746.

78. Link A, Girndt M, Selejan S, Rbah R, Böhm M. Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Crit Care. 2008; 12(4):R111.

79. Colella V, Zarrillo N, D'Amico M, Forfori F, Pezza B. Argatroban anticoagulation during polimixina-B (PMB) hemoperfusion. Int Care Med Exp. 2016; 4(Suppl 1):A384.

80. Deep A, Zoha M, Kukreja PD. Prostacyclin as anticoagulant for Continuous Renal Replacement Therapy in Children, Blood Purif. 2017; 43:279–289.

81. Nongnuch A, Tangsujuritvijit V, Davenport A. Anticoagulation for renal replacement therapy for patients with Acute Kidney Injury. Minerva Urol Nephrol. 2016; 68(1):87–104.
82. Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs. 2016; 39(1):16–21.

83. Arimura T, Abe M, Shiga H, Katayama H, Kaizu K, Oda S. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. J Artif Organs. 2017; 20(3):244–251.

84. Choi JY, Kang YJ, Jang HM, et al. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients with High Bleeding Risk: A Randomized Clinical Trial. Medicine (Baltimore). 2015; 94(52):e2392.

85. Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: A Retrospective Pilot Observational Study. Kobe J Med Sci. 2017; 63(1):E30–E36.

86. Schetz M. Anticoagulation for continuous renal replacement therapy. Curr Opin Anaesthesiol 2001; 14:143–149.

87. Bai M, Zhou M, He L, Ma F, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive care medicine 2015; 41(12):2098–2110.

88. Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019; 23(1):22.

89. Joannidis M, Oudermans-van Straaten H. Clinical review: Patency of the circuit in continuous renal replacement therapy. Critical Care 2007; 11:218.

90. Brain M, Winson E, Roodenburg O, McNeil J. Non-anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017; 18(1):69.
